Market Place
Sourcing Support
ExeVir Announces Michael Garrett as New Chief Executive Officer
18 Nov 2024 //
GLOBENEWSWIRE
ExeVir Bio presents promising XVR013m data at ID Week 2024
17 Oct 2024 //
GLOBENEWSWIRE
ExeVir Bio: XVR013m Potent Against SARS-CoV-2 Variant JN1
04 Jun 2024 //
GLOBENEWSWIRE
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012
15 Jan 2024 //
GLOBENEWSWIRE
ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research
28 Jun 2023 //
GLOBENEWSWIRE
ExeVir Bio and VIB Announce Data on a New Therapy for Treatment for COVID-19
13 Mar 2023 //
GLOBENEWSWIRE
ExeVir secures EUR 25M venture debt financing from European Investment Bank
09 Jan 2023 //
GLOBENEWSWIRE
ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy
20 Oct 2022 //
PRNEWSWIRE
ExeVir hits pause on llama-derived Covid antibody amid Omicron variants
09 May 2022 //
ENDPTS
ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study
01 Sep 2021 //
PRNEWSWIRE
ExeVir doses first patients with llama-derived anti-Covid antibody
18 Aug 2021 //
ENDPOINTS
ExeVir, Mithra CDMO Enter Manufacturing Collaboration
21 Jul 2021 //
CONTRACT PHARMA
ExeVir and Mithra announce manufacturing collaboration
15 Jul 2021 //
PR NEWSWIRE
ExeVir and Mithra announce manufacturing collaboration for Covid-19 treatments
14 Jul 2021 //
PRNEWSWIRE
ExeVir and Mithra announce manufacturing collaboration for Covid-19 treatments
14 Jul 2021 //
PRNEWSWIRE
ExeVir`s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern
13 Jul 2021 //
PRNEWSWIRE
ExeVir`s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern
13 Jul 2021 //
PRNEWSWIRE
ExeVir Announces Close of US$50 million / EUR42 million Series A Financing
16 Mar 2021 //
PRNEWSWIRE
ExeVir Bio Announces New Publication from VIB Scientists Showing Potent
09 Mar 2021 //
PRNEWSWIRE
ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors
02 Nov 2020 //
PRNEWSWIRE
UCSF engineers develop llama-inspired `AeroNabs` to fight COVID
17 Aug 2020 //
FIERCEBIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.